Open AccessEffectiveness of Oral Tofacitinib Dose Tapering in a Case of Alopecia Areata Universalis
Author(s) -
Mariana Esteves,
Sofia Lopes,
Filomena Azevedo,
Ana Catarina Pedrosa
Publication year - 2020
Publication title -
skin appendage disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.773
H-Index - 13
eISSN - 2296-9195
pISSN - 2296-9160
DOI - 10.1159/000510673
Subject(s) - alopecia areata , alopecia universalis , tofacitinib , medicine , dermatology , refractory (planetary science) , minoxidil , hair loss , rheumatoid arthritis , physics , astrobiology
Alopecia areata (AA) is a form of nonscarring alopecia and one of the most common autoimmune disorders. Persistent or severe variants lead to potential disfigurement and are associated with a significant negative impact on the patient’s quality of life. Case Presentation: A 51-year-old female patient presenting with refractory alopecia universalis was successfully treated with oral tofacitinib. Recurrence was not observed following 17 months of therapy. Discussion/Conclusion: None of the currently employed therapies for AA are reliably effective nor are they approved for the disease. In this setting, Janus kinase inhibitors emerge as a promising novel treatment, as increasing evidence supports their effectiveness in AA.